Population pharmacokinetics‐pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease

BACKGROUND: Vedolizumab, an anti‐α(4)β(7) integrin monoclonal antibody (mAb), is indicated for treating patients with moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD). As higher therapeutic mAb concentrations have been associated with greater efficacy in inflammato...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Aliment Pharmacol Ther
Hlavní autoři: Rosario, M., Dirks, N. L., Gastonguay, M. R., Fasanmade, A. A., Wyant, T., Parikh, A., Sandborn, W. J., Feagan, B. G., Reinisch, W., Fox, I.
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley and Sons Inc. 2015
Témata:
Inflammatory Bowel Disease
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5032981/
https://ncbi.nlm.nih.gov/pubmed/25996351
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/apt.13243
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky